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Involvement of IL-1 in tumor cell growth was first observed in subclones ofa
murine T cell lymphoma (1). On EBV-transformed B cell lines, including VDS-
O, both IL-la and IL-I# have been reported to share the same receptor (2).
This suggests that IL-1 plays a role in autocrine control of VDS-O cell prolifer-
ation, since these cells produced IL-1 and proliferated after its addition, though
the effects ofanti-IL-1 antibodies on proliferation ofthese cells were not studied
(2, 3). Subsequent isolation of the genes coding for IL-1 has enabled studies on
the effects of rIL-1 free of contaminating materials, and measurement of the
genes' intracellular expression (4, 5). In this study, the effects ofrIL-1 and other
recombinant hematopoietic factorson proliferation andCD25antigen expression
by acute myelogenous leukemia (AML) cells were examined.
Materials and Methods
Patients. Five patients with AML were examined, and diagnosed according to the
French-American-British (FAB) classification (6, 7). Electron microscopic studies of plate-
let peroxidase (PPO) activity were performed according to the method of Breton-Gorius
et al. (8).
Cell Culture. Leukemic blasts were obtained from either peripheral blood or bone
marrow by Ficoll-Conray density gradient centrifugation. The relative proportionofblasts
in each cell suspension always exceeded 90%. Purified leukemic cells (106 cells/ml) were
cultured at 37°C in the presence or, absence of various reagents, in complete medium
(RPMI 1640 medium supplemented with 100 U/ml penicillinG, 100,ug/ml streptomycin,
and 10% FCS) and a humidified atmosphere of 5% C02 in air. Human rIL-2, rIL-la,
rIL-1,5, granulocyte/macrophage colony-stimulating factor (GM-CSF), and gibbon rIL-3
were obtained from Takeda Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co.
Ltd., Otsuka Pharmaceutical Co. Ltd., and the Genetics Institute, respectively. Specific
rabbit antibodies against IL-la and IL-1,8 were provided by Dainippon Pharmaceutical
Co. Ltd. and Otsuka Pharmaceutical Co. Ltd., respectively.
[3H]TdR incorporation of leukemic cells was measured as described previously (9).
Cell Surface Marker Analysis.
￿
Cell surface markers were analyzed by laser flow cytom-
etry (Spectrum III; Ortho Diagnostic Systems Inc., Westwood, MA). mAbs used were
MCS-2(CD13), anti-Tac (CD25) (kindly provided by Dr. T. Uchiyama at Kyoto University,
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Kyoto, Japan), phycoerythrin (PE)-conjugated anti-IL-2-R antibody (CD25) (Becton-Dick-
inson Monoclonal Center, Mountain View, CA), anti-platelet-associated glycoprotein
IIb/11Ia (CDw41) (Immunotech, Marseille, France), T11 (CD2), and B4 (CD19) (Coulter
Immunology, Hialeah, FL) . To prevent nonspecific binding of mAb to cell surface Fc
receptors, mAb was always incubated in the presence of 50 Al heat-inactivated human AB
serum (9) . Two-color fluorescence analysis was performed on cells sequentially stained
with anti-CD13 mAb and FITC-conjugated goat anti-mouse IgG followed by PE-conju-
gated anti-CD25 mAb, and the data were analyzed by a DS-1 computer equipped with a
program developed at Ortho Diagnostic Systems Inc . according to the original program
(10).
IL-1 Activity in Culture Supernatants . Crude conditioned media were prepared as
described elsewhere (11). IL-1 activity in the culture supernatants was examined by
thymocyte comitogenic activity, though with minor modifications (11) .
Detection ofIL-1 Gene Expression .
￿
Northern blot analysis was performed according to
the established methods (12) . IL-I fl mRNA was detected using a 0.6-kb segmentof IL-10
cDNA (kindly provided by Dr . J . Yodoi at Kyoto University), which had been labeled to
a specific activity of 10 9 cpm/wg with oligonucleotide primersand [s2P]dCTP,as previously
described (13) . Hybridization was performed by immersion of the membranes with the
radiolabeled IL-1,B probe at 42°C for 6 h. The washed membranes were dried and then
exposed to x-ray film at -80 °C. U937 and HPB-ALL cell lines were also used as positive
and negative controls, respectively .
Results
Surface Markers and Proliferation of Cells.
￿
Leukemic cells from five patients
with AML (one with M1, one with M2, one with M5b, and two with M7) were
examined . Surface marker analysis with mAbs CD2 and CD19 revealed that
contamination with normal lymphocytes in cell suspensions was <10% .
CD25 antigen was detected on cells from two M7 AML patients, while studies
into induction of its expression by, and effects on cell proliferation ofIL-la and
IL-1,8 (1-100 U/ml) found that both marked proliferation and CD25 antigen
expression were stimulated only in cultures of cells from one M7 AML patient
(HN) (Table I) . Since the spontaneous proliferation rate measured by [sH]TdR
incorporation was greater among HN cells (48,800 cpm) than among any of the
others (5,500-32,800 cpm), and because CD25 antigen expression increased
after cultivation with medium alone, as described below, the involvement of IL-
1 in HN cell proliferation and CD25 antigen expression was suspected. Addition
of rabbit anti-IL-1,8 antibody to these cells specifically inhibitedproliferation and
expression of CD25 antigen (Table I) .
To test whether other well known hematopoietic growth factors also regulated
proliferation and expression of CD25 antigen on HN cells, the effects of IL-2
(10-100 U/ml), GM-CSF (10-100 U/ml), and IL-3 (10-100 U/ml) were studied,
but were found to influence neither .
Freshly isolated patient HN leukemic cells showed the following percent cell
surface marker expression : 40.3% CD13, 18.9% CD25, 56.5% CD7, 54.2%
CDw4l, 1.3% CD2, and 0.6% CD19, and after cultivation for 24 h in complete
medium, their surface markers were as follows : 88.6% CD13, 54.5% CD25,
32.4% CD7, 76.5% CDw41, 1 .9% CD2, and 0.8% CD19 . Thus, contamination
withnormalT or B cells in cell suspensionswas<5%, beforeandafter cultivation,
suggesting that CD25 antigen was expressed on the leukemic cells . To clarify
this, cells that had been stored in liquid nitrogen were examined by two-colorSAKAI ET AL.
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TABLE I
Effect ofIL-1 and Anti-IL-1 Ab on CD25 Ag Expression and
Proliferation of Leukemic Cells
* Percentage of cells positive for CD25 antigen. NT, not tested.
x Data represent mean t SD of quadruplicate samples (X 10' cpm).
TABLE II
IL-1 Activity in Culture Supernatants
* Mean t SD of quadruplicate samples.
* Anti-IL-I antibodies and preimmune normal rabbit sera (NRS) were used at final dilutions of
1 :1,000. Percent suppression wascalculated as: 100 X (1 - [(cpm in the presence ofantibody)/(cpm
in the absence ofantibody)][.
fluorescence, since fresh leukemic cells were no longer available. Only 33.7% of
medium-cultured frozen leukemic cells expressed both CD13 and CD25 antigens,
and its further induction by IL-Iß (100 U/ml) was not observed. However, the
relative proportions of cells bearing both markers decreased to 24.7% when
cultured with anti-IL-lß antibody.
IL-1 Activity in Culture Supernatants. The mouse thymocyte comitogenic
proliferation assay detected IL-1 activity in HN leukemic cell culture superna-
tants. This activity was specifically blocked by anti-IL-Iß antibody in a dose-
dependent manner, but not by either anti-IL-la antibody or preimmune normal
rabbit sera (NRS) (Table II).
Northern Blot Analysis.
￿
Toinvestigate the regulation ofIL-lß gene expression
in HN cells, transcription was examined by Northern blot analysis of RNA
extracted from fresh or cultured cells. IL-lß gene expression was observed in
fresh HN cells and in PMA-stimulated U937 cells, but not in HPB-ALL cells.
Antibody Concentration or
dilution
CD 25 Ag
expression ['H]TdR uptake*
cpm
Medium - 54.5 48.8 t 6.6
IL-la 1 U/ml NT 65.2 t 10.2
10 U/ml 67.2 158.8 ± 10.4
100 U/ml 70.1 155.4 t 11 .5
IL-10 1 U/ml NT 47.2 t 7.3
10 U/ml 69.7 115.7 t 9.7
100 U/ml 72.1 180.4 t 30.6
anti-IL-la 1 :10' 55.2 49.2 t 3.1
anti-IL-IS 1 :10' 53.2 47.5 t 4.1
1 :10' 48.4 39.0 t 3.3
1 :10' 32.9 28.1 t 3.0
NRS 1 :10' 55.8 50.5 t 5.I
Sources
Medium
Concentration
or final
dilution
1 :4
['H]TdR uptake*
cpm
830 ± 60
Anti-IL-la
Suppression=
Anti-IL-lß NRS
IL-la 100 U/ml 24,930 t 2,010 92.5 -2.1 -3.1
IL-10 100 U/ml 27,740 t 1,090 -1.1 88.6 0.6
M7 AML (HN) 1 :4 36,200 t 1,520 10.9 85.9 9.6
1 :12 18,280 t 1,530 -12,0 89.1 -10.6
1 :36 7,120 t 680 9.2 87,5 -11 .51600
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FIGURE 1 . Northern blot analysis of IL-1fl gene
expression in AML cells and cell lines . RNAs were
isolated from M7 AML (HN) cells. (1) Cells freshly
obtained, (2) cells cultured in complete medium, and
(3) cells cultured with IL-1/3. (4) PMA-treated U937
cells, and (5) HPB-ALL cells . Equal amounts of each
RNA (10 gg/lane) were analyzed by Northern blot
hybridization, using a "P-labeled IL-10 probe .
Furthermore, levels of IL-1,Q gene expression were higher in IL-1-treated HN
cells than in those cultivated in medium alone (Fig . 1) .
Discussion
This paper presented the results of a study in which leukemic cells from an
M7AML patient proliferated in the presence of IL-1,Q,which in addition, induced
the cells to express CD25 antigen . The leukemic cells' culture supernatants
contained IL-10 activity, and expression of their IL-10 genes was confirmed by
Northern blot hybridization .
Recently, Young et al . detected GM-CSF transcription in leukemic cells of 11
of22 patients with AML, and found biologically active CSF activity inAML cell-
conditioned media . Furthermore, autocrine stimulation of GM-CSF expression
in AML cells has also been reported by this group (14, 15) . It is also known that
IL-1 induces production of GM-CSF by endothelial cells (16) . Thus, we initially
thought that IL-1 might induce GM-CSF in AML cells, which would in turn
promote AML cell proliferation . However, in these experiments we were unable
to detect any GM-CSF effects on proliferation or CD25 antigen expression .
Proliferation and induction of IL-10 gene transcription in HN cells by IL-1,8,
and production of IL-10 by these cells, strongly suggests that autocrine stimula-
tion of IL-10 plays a role in proliferation of these cells . Infusions of IL-1 have
been reported to cause neutrophilia in mice (17), while recently, it was also
reported (18, 19) that IL-1 constituted one component of hemopoietin-1, which
is believed to induce mouse stem cells to become responsive to other CSFs . The
leukemic cells in our study possessed CD7, CD25, and CDw41 antigens, suggest-
ing that they originated from pluripotent stem cells. Thus our findings described
here suggest that IL-1 directly promotes proliferation ofhuman myeloid progen-
itor cells . However, the leukemic cells from the other M7 patient, which had
surface markers similar to those of theHN cells, neither responded to IL-1 nor
produced it, suggesting that the involvement of IL-1 in AML is not universal
and showing that we were unable to define the exact relationship between the
stages of this leukemia and IL-1 production . Nevertheless, our study suggests
that IL-1 is involved in proliferation of some myeloid leukemia cells, and that
interference with IL-1 activity might be beneficial in treatment ofAML .Summary
A significant increase in CD25 antigen-positive cells by IL-1 was observed in
cells of a patient with M7 acute myelogenous leukemia. Basal proliferation and
expression of CD25 antigen by the M7 leukemic cells were inhibited by addition
of anti-IL-1# antibody in a dose-dependent manner, but not by rabbit anti-IL-
1a antibody. Culture supernatants of these leukemic cells contained IL-1 activity,
which was specifically inhibited by addition of anti-IL-1,8 antibody, and Northern
blot analysis detected intracellular IL-1,8 mRNA. These results indicated that
autocrine secretion of IL-If was involved in proliferation of some myelogenous
leukemic cells.
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